Annovis Announces $6 Million Registered Direct Offering of Common Stock
Rhea-AI Summary
Annovis (NYSE: ANVS) entered into definitive agreements to sell an aggregate of 4,000,000 shares of common stock (or pre-funded warrants) at $1.50 per share in a registered direct offering, with expected gross proceeds of approximately $6 million. Closing is expected on or about October 13, 2025, subject to customary conditions. H.C. Wainwright & Co. is the exclusive placement agent. The company intends to use net proceeds for working capital and general corporate purposes. The offering is being made under a shelf registration (Form S-3, Reg. No. 333-276814) with a prospectus supplement to be filed with the SEC.
Positive
- Aggregate gross proceeds of approximately $6 million
- Definitive agreements executed for 4,000,000 shares at $1.50 per share
- Proceeds earmarked for working capital and general corporate purposes
- Offering conducted under an already effective Form S-3 shelf registration
Negative
- Issuance of 4,000,000 shares may cause notable shareholder dilution
- Placement agent fees and offering expenses will reduce net proceeds
- Closing is subject to customary conditions and may not occur on the expected Oct 13, 2025 date
News Market Reaction
On the day this news was published, ANVS declined 22.73%, reflecting a significant negative market reaction. Argus tracked a trough of -26.0% from its starting point during tracking. Our momentum scanner triggered 14 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $13M from the company's valuation, bringing the market cap to $43M at that time.
Data tracked by StockTitan Argus on the day of publication.
MALVERN, Pa., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it has entered into definitive agreements for the purchase of an aggregate of 4,000,000 shares of its common stock (or pre-funded warrants in lieu thereof) at a purchase price of
H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering.
The aggregate gross proceeds to the Company from the offering are expected to be approximately
The securities described above are being offered and sold by the Company pursuant to a “shelf” registration statement on Form S-3 (Registration No. 333-276814), including a base prospectus, previously filed with the Securities and Exchange Commission (SEC) on February 1, 2024 and declared effective by the SEC on February 12, 2024. The offering is being made only by means of a prospectus supplement that forms a part of the registration statement. A prospectus supplement and an accompanying base prospectus relating to the offering will be filed with the SEC and will be available on the SEC’s website located at http://www.sec.gov. Electronic copies of the prospectus supplement and accompanying base prospectus may also be obtained, when available, by contacting H.C. Wainwright & Co., LLC at 430 Park Avenue, 3rd Floor, New York, NY 10022, by phone at (212) 856-5711 or e-mail at placements@hcwco.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.
About Annovis
Headquartered in Malvern, Pennsylvania, Annovis is dedicated to addressing neurodegeneration in diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). The Company is committed to developing innovative therapies that improve patient outcomes and quality of life. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Forward-Looking Statements
This press release contains forward-looking statements under the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding the consummation of the offering, the satisfaction of closing conditions and the use of proceeds from the offering. Actual results may differ due to various risks and uncertainties, including those outlined in the Company’s SEC filings under “Risk Factors” in its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no obligation to update forward-looking statements except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Alexander Morin, Ph.D.
Director, Strategic Communications
Annovis Bio
ir@annovisbio.com
FAQ
What is Annovis (ANVS) raising in the October 2025 registered direct offering?
When is the Annovis (ANVS) offering expected to close?
How does Annovis (ANVS) plan to use the net proceeds from the offering?
Who is the placement agent for Annovis (ANVS) registered direct offering?
Where can investors find the prospectus for the ANVS registered direct offering?
What immediate shareholder impacts should investors expect from the ANVS offering?
